| Literature DB >> 33853868 |
Andrea Chambers1, Cynthia Chen2,3, Kevin Antoine Brown2,3,4, Nick Daneman2,3,5, Bradley Langford2, Valerie Leung2, Kwaku Adomako2, Kevin L Schwartz2,4, Julia E Moore6, Jacquelyn Quirk2, Sam MacFarlane2, Tim Cronsberry2, Gary E Garber2,7.
Abstract
BACKGROUND: Urine culturing practices are highly variable in long-term care and contribute to overprescribing of antibiotics for presumed urinary tract infections. The purpose of this study was to evaluate the use of virtual learning collaboratives to support long-term care homes in implementing a quality improvement programme focused on reducing unnecessary urine culturing and antibiotic overprescribing.Entities:
Keywords: antibiotic management; implementation science; nursing homes; quality improvement
Mesh:
Substances:
Year: 2021 PMID: 33853868 PMCID: PMC8785008 DOI: 10.1136/bmjqs-2020-012226
Source DB: PubMed Journal: BMJ Qual Saf ISSN: 2044-5415 Impact factor: 7.035
Figure 1Description of sample, recruitment and allocation results.
Adoption of recommended implementation strategies among participating long-term care homes (n=32)
| Implementation strategy description | Complete | Incomplete* | No response† |
| Readiness strategies | |||
| Consensus: ensuring agreement on the practices among prescribers | 24 (75) | 5 (16) | 3 (9) |
| Policies and procedures: ensuring policies and procedures are aligned with five practice changes | 23 (72) | 6 (19) | 3 (9) |
| Champion: selecting a champion and involving them in implementation | 21 (66) | 8 (25) | 3 (9) |
| Local opinion leaders: finding way for prescribers to be involved in delivering strategies | 19 (59) | 10 (31) | 3 (9) |
| Implementation team: having at least three people that are part of an implementation team | 15 (47) | 14 (44) | 3 (9) |
| Education and support | |||
| Delivering education to staff | 27 (84) | 1 (3) | 4 (13) |
| Coaching: ensuring there is someone to help with questions/concerns after education | 25 (78) | 3 (9) | 4 (13) |
| Providing information/education to residents and families | 25 (78) | 3 (9) | 4 (13) |
| Monitoring and communication | |||
| Resident symptoms: addressing improvement in how resident symptoms are documented and communicated | 26 (81) | 1 (3) | 5 (16) |
| Reminders: looking for opportunities to remind staff about the practice changes | 23 (72) | 4 (13) | 5 (16) |
| Process surveillance: checking records of urine cultures and antibiotics prescribed for UTIs to see how they are aligned with the programme algorithm | 22 (69) | 5 (16) | 5 (16) |
*Incomplete refers to LTCHs that indicated they did not complete this strategy.
†No response refers to LTCHs that did not complete the survey or question. Proportions reflect the total number of participating LTCHs and not the total number of LTCHs that responded to the survey.
LTCHs, long-term care homes; UTI, urinary tract infection.
Baseline characteristics of residents and long-term care homes (LTCHs)
| Characteristics | Matched intervention LTCHs | Matched control LTCHs | Standardised differences* |
| Bed size†, mean (SD) | 128.3 (70.8) | 136.2 (76.8) | −0.11 |
| Region | |||
| Urban (%) | 33 (77) | 106 (84) | −0.17 |
| Rural (%) | 10 (23) | 21 (17) | |
| Mean rate at baseline per 1000 resident days | |||
| Urine culturing† (IQR) | 4.0 (2.5–5.5) | 3.4 (2.2–4.9) | 0.15 |
| Total antibiotic prescriptions† (IQR) | 4.2 (3.7–5.1) | 4.4 (3.5–5.2) | 0.05 |
| Urinary antibiotic prescriptions (IQR) | 1.5 (1.2–2.0) | 1.4 (1.1–1.8) | 0.08 |
| Hospital admissions (IQR) | 1.7 (1.4–2.3) | 2.0 (1.6–2.5) | −0.40 |
| No. unique residents | 7960 | 24 827 | |
| Mean resident age (SD) | 85.17 (8.1) | 84.79 (8) | 0.05 |
| Female proportion (%) | 5515 (69) | 17 023 (69) | 0.02 |
| Comorbidities, n (%): | |||
| Residents with severe cognitive impairment‡ | 2857 (36) | 8818 (36) | 0.01 |
| Dementia and Alzheimer’s disease | 5423 (68) | 16 713 (67) | 0.02 |
| Paralysis | 14 (0.2) | 110 (0.4) | −0.05 |
| Parkinson’s disease | 550 (7) | 1649 (7) | 0.01 |
| Obstructive lung disease | 1510 (19) | 4475 (18) | 0.02 |
| Cancer | 768 (10) | 2812 (11) | −0.06 |
| Gastrointestinal disease | 2546 (32) | 7055 (28) | 0.08 |
| Liver disease | 94 (1) | 365 (2) | −0.03 |
| Diabetes mellitus | 2229 (28) | 7173 (29) | −0.02 |
| Renal disease | 775 (10) | 2815 (11) | −0.05 |
| Atherosclerotic heart disease | 1367 (17) | 4172 (17) | 0.01 |
| Congestive heart failure | 1156 (15) | 3210 (13) | 0.05 |
| Peripheral vascular disease | 555 (7) | 1521 (6) | 0.03 |
| Stroke | 2055 (26) | 6392 (26) | 0.002 |
| Functional status, n (%) | |||
| Bladder incontinence | 7337 (92) | 22 412 (90) | 0.07 |
| Bowel incontinence | 6371 (80) | 19 513 (79) | 0.04 |
| Devices, n (%) | |||
| Indwelling catheter | 582 (7) | 1526 (6) | 0.05 |
| Other urinary catheter | 40 (0.5) | 212 (0.9) | −0.04 |
| Feeding tube | 56 (0.7) | 241 (1.0) | −0.03 |
*A threshold of ≤0.1 is recommended to consider differences between groups.
†Variables used to match intervention to control LTCHs.
‡Cognitive Performance Scale ≥4.
Figure 2Rates of urine culturing, urinary antibiotic prescriptions and total antibiotic prescriptions per 1000 resident days (RD) for intervention and matched control long-term care homes (LTCHs), November 2016–December 2019.
Baseline and postimplementation rates in the intervention and control facilities and difference-in-difference estimates for the intention-to-treat analysis
| Outcome | Control (n=127) | Intervention (n=43) | Difference-in-difference | ||||
| Before mean (SD) | After mean (SD) | Before mean (SD) | After mean (SD) | Estimate† | SE | 95% CI | |
| Urine culturing | 3.8 (2.2) | 3.4 (2.0) | 4.1 (1.9) | 3.1 (2.1) | −0.21** | 0.02 | −0.24 to to 0.17 |
| Urinary antibiotics | 1.5 (0.7) | 1.0 (0.5) | 1.6 (0.7) | 0.9 (0.5) | −0.13** | 0.03 | −0.19 to to 0.07 |
| Total antibiotics | 4.4 (1.1) | 3.6 (1.2) | 4.4 (1.2) | 3.5 (1.1) | −0.05* | 0.02 | −0.08 to to 0.01 |
| Acute care admission | 2.1 (0.8) | 2.0 (0.7) | 1.8 (0.6) | 1.8 (0.7) | 0.01 | 0.02 | −0.03 to 0.06 |
| Mortality | 1.8 (0.6) | 1.9 (0.7) | 1.9 (0.4) | 2.1 (0.6) | 0.01 | 0.04 | −0.06 to 0.09 |
*P<0.01; **p<0.0001.
†From the difference-in-difference estimate (Poisson random-effects model). Before=baseline period from November 2016–April 2018. After=postimplementation period from September 2018–December 2019.